Phase 4 N=15 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Glaucoma · Dry Eyes
Primary: Ocular Surface Staining — 1.65 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,018 PROTECT Continued Access Post Marketing Surveillance Trial
Coronary Artery Disease, Autosomal Dominant, 1
Primary: To Evaluate Overall Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System in a Patient Population Requiring Stent Implantation — 1.2…
Phase 4 N=19 Study of EXPAREL in Patients Undergoing Breast Augmentation
Mammoplasty · Postoperative Pain
Primary: Duration of Analgesia — 0.07; 0.3; 4.28; 4.82 hours
Phase 4 N=201 A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
Rheumatoid Arthritis
Primary: Health Assessment Questionnaire (HAQ) Score — 1.93; 1.49; 1.22; 1.08 units on a scale
Phase 4 N=30 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Tourette Syndrome
Primary: The Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS) — 6.2; 10.5; 10.2 units on a scale
Phase 4 N=54 Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
Glaucoma · Ocular Hypertension · Open-angle Glaucoma
Primary: Change in IOP at the Final Visit From Prior Brimonidine 0.2%/Timolol 0.5% Fixed Combination (COMBIGAN®) Therapy (i.e. From Baseline) — 22.24; -2.24 mmHg
Phase 4 N=124 Quetiapine Augmentation for Treatment-resistant PTSD
Combat Disorders · Stress Disorders, Post-Traumatic
Primary: Change in Clinician-Administered PTSD Scale for DSM-IV Total Score. — 72.15; 68.78; 67.90; 51.52 units on a scale — p=<0.05
Phase 4 N=360 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage
Spinal Cord Injury
Primary: Quality of Bowel Preparation — 3.4; 2.5; 3.6; 7.4 units on a scale
Phase 4 N=22 Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
Transplant Rejection
Primary: Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam With and Without the Coadministration of Belatacept - Pharmacokinetic (PK) Evaluable Population…
Phase 4 N=20 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
Depression
Primary: Number of IL-2 Treatments Tolerated — 18.4; 19.8 IL-2 treatments
Phase 4 N=109 AZISAST Study: AZIthromycin in Severe ASThma Study
Asthma
Primary: Proportion of Participants With Severe Asthma Exacerbations — 0.52; 0.55 proportion of participants
Phase 4 N=26 Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
Phase 4 N=48 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake
Alcohol Abuse
Primary: Alcohol Consumption in Drinks/Week. — 83.43; 75.97 number of drinks
Phase 4 N=17 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
End-stage Renal Disease · Cardiovascular Disease
Primary: Pharmacokinetic Parameters of Ranolazine — 0.65 mcg/mL
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants